Bausch Health Companies (NYSE:BHC) Rating Lowered to Hold at StockNews.com

Bausch Health Companies (NYSE:BHC) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Tuesday.

Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada decreased their price target on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler upped their target price on shares of Bausch Health Companies from $7.00 to $9.00 and gave the stock a “neutral” rating in a research report on Monday, April 29th. Finally, Jefferies Financial Group reduced their price target on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold” and a consensus price target of $11.33.

Bausch Health Companies Trading Down 5.2 %

BHC opened at $7.03 on Tuesday. Bausch Health Companies has a 12-month low of $5.57 and a 12-month high of $11.46. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -5.67 and a beta of 0.90. The company’s 50 day moving average is $9.16 and its 200 day moving average is $8.21.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 2,370.91%. The company’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.02 EPS. As a group, analysts predict that Bausch Health Companies will post 3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Group AG raised its position in Bausch Health Companies by 127.9% during the third quarter. UBS Group AG now owns 394,232 shares of the company’s stock valued at $3,241,000 after purchasing an additional 221,213 shares during the period. Readystate Asset Management LP purchased a new position in shares of Bausch Health Companies during the 4th quarter worth about $2,933,000. Deutsche Bank AG grew its holdings in Bausch Health Companies by 1,397.8% during the 3rd quarter. Deutsche Bank AG now owns 362,850 shares of the company’s stock valued at $2,983,000 after purchasing an additional 338,624 shares during the last quarter. Vanguard Group Inc. lifted its stake in Bausch Health Companies by 1.6% in the third quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company’s stock worth $94,429,000 after purchasing an additional 175,489 shares during the last quarter. Finally, Segantii Capital Management Ltd boosted its position in shares of Bausch Health Companies by 20.0% during the third quarter. Segantii Capital Management Ltd now owns 3,000,000 shares of the company’s stock valued at $24,660,000 after buying an additional 500,000 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.